Cardiopulmonary hemodynamics for accurate diagnosis of portopulmonary hypertension: A redefinition to consider
Mateo Porres‐Aguilar, Debabrata Mukherjee – 22 May 2014
Treatment response in the PIVENS trial is associated with decreased hedgehog pathway activity
Cynthia D. Guy, Ayako Suzuki, Manal F. Abdelmalek, James L. Burchette, Anna Mae Diehl, for the NASH CRN – 22 May 2014 – Hedgehog (Hh) ligand production by ballooned hepatocytes drives nonalcoholic steatohepatitis (NASH) progression in mice. The NIDDK‐sponsored PIVENS trial (NCT00063622) showed that vitamin E (VitE) improved NASH. We investigated whether VitE treatment and improvement in NASH were associated with changes in Hh pathway activity.
Dual role of B7 costimulation in obesity‐related nonalcoholic steatohepatitis and metabolic dysregulation
Antonios Chatzigeorgiou, Kyoung‐Jin Chung, Ruben Garcia‐Martin, Vasileia‐Ismini Alexaki, Anne Klotzsche‐von Ameln, Julia Phieler, David Sprott, Waldemar Kanczkowski, Theodora Tzanavari, Mohktar Bdeir, Sibylle Bergmann, Marc Cartellieri, Michael Bachmann, Polyxeni Nikolakopoulou, Andreas Androutsellis‐Theotokis, Gabriele Siegert, Stefan R. Bornstein, Michael H. Muders, Louis Boon, Katia P.
Etanercept blocks inflammatory responses orchestrated by TNF‐α to promote transplanted cell engraftment and proliferation in rat liver
Preeti Viswanathan, Sorabh Kapoor, Vinay Kumaran, Brigid Joseph, Sanjeev Gupta – 21 May 2014 – Engraftment of transplanted cells is critical for liver‐directed cell therapy, but most transplanted cells are rapidly cleared from liver sinusoids by proinflammatory cytokines/chemokines/receptors after activation of neutrophils or Kupffer cells (KCs). To define whether tumor necrosis factor alpha (TNF‐α) served roles in cell‐transplantation–induced hepatic inflammation, we used the TNF‐α antagonist, etanercept (ETN), for studies in syngeneic rat hepatocyte transplantation systems.
First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: Complete remission followed by lethal sepsis
Benedikt Schaefer, Michael Steurer, Bernhard Glodny, Daniel Neureiter, Patrizia Moser, Livia Dorn, Wolfgang Vogel, Heinz Zoller – 21 May 2014
Reply
Reena Mourya, Kazuhiko Bessho, Pranavkumar Shivakumar, Jorge A. Bezerra – 21 May 2014
Diabetes mellitus is an independent prognostic factor for major liver‐related outcomes in patients with cirrhosis and chronic hepatitis C
Laure Elkrief, Pascale Chouinard, Noelle Bendersky, David Hajage, Béatrice Larroque, Gérard Babany, Blaise Kutala, Claire Francoz, Nathalie Boyer, Richard Moreau, François Durand, Patrick Marcellin, Pierre‐Emmanuel Rautou, Dominique Valla – 20 May 2014 – In patients with chronic hepatitis C (CHC), cirrhosis is associated with age, gender, diabetes, alcohol abuse, and coinfection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV). The effect of these factors on the outcome of cirrhosis is unknown.
Hepatic expression of interleukin 8 in diagnosing biliary atresia
Rui Dong, Gong Chen, Shan Zheng, Harry Hua‐Xiang Xia – 20 May 2014
Shotgun proteomics: Identification of unique protein profiles of apoptotic bodies from biliary epithelial cells
Ana Lleo, Weici Zhang, W. Hayes McDonald, Erin H. Seeley, Patrick S.C. Leung, Ross L. Coppel, Aftab A. Ansari, David H. Adams, Simon Afford, Pietro Invernizzi, M. Eric Gershwin – 20 May 2014 – Shotgun proteomics is a powerful analytic method to characterize complex protein mixtures in combination with multidimensional liquid chromatography‐tandem mass spectrometry (LC‐MS/MS).
Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: A cohort study using the United Network for Organ Sharing registry
Barry Schlansky, Yiyi Chen, David L. Scott, Donald Austin, Willscott E. Naugler – 18 May 2014 – Recipients of liver transplantation (LT) for hepatocellular carcinoma (HCC) have an 8% to 20% risk of HCC recurrence. Single‐center studies suggest that a period of waiting after HCC therapy may facilitate the selection of patients at low risk for post‐LT HCC recurrence and mortality. We evaluated whether a longer waiting time after Model for End‐Stage Liver Disease (MELD) prioritization for HCC predicts longer post‐LT survival.